PTGS2 and lung adenocarcinoma: Furthermore, the ability of the COX-IS to independently predict the outcome after ICB suggests a role for COX2/PGE2 signaling in hindering responses to ICB in patients with lung adenocarcinoma, supporting previous findings in other cancer types (31).